FAS and metabolic dysfunction-associated steatotic liver disease: These observations are in agreement with previous studies that have shown that shorter periods of n-3 PUFA (EPA and/or DHA) supplementation have beneficial effects on different experimental models of NAFLD in younger animals by decreasing the levels/activity of key regulators of hepatic fatty acid synthesis and lipogenesis, including FAS, SCD1, DGATs, and SREBP1c [27,35,79,80,84,85,86].